Filing Details
- Accession Number:
- 0000950170-24-021575
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-02-27 20:00:20
- Reporting Period:
- 2024-02-23
- Accepted Time:
- 2024-02-27 20:00:20
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1567514 | Intra-Cellular Therapies Inc. | ITCI | () | 4 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1521548 | Michael Halstead | C/O Intra-Cellular Therapies, Inc. 430 East 29Th Street New York NY 10016 | Evp And General Counsel | No | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2024-02-23 | 7,907 | $0.00 | 7,907 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2024-02-26 | 300 | $68.54 | 7,607 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2024-02-26 | 7,215 | $69.54 | 392 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2024-02-26 | 392 | $70.13 | 0 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Restricted Stock Units | Disposition | 2024-02-23 | 7,907 | $0.00 | 7,907 | $0.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | No | 4 | M | Direct |
Footnotes
- Restricted stock units convert into common stock on a one-for-one basis.
- This sale was effected pursuant to a Rule 10b5-1 trading plan originally adopted by the reporting person on March 15, 2023 and amended on May 8, 2023 and August 11, 2023. A majority of the proceeds from this sale will be used to cover the reporting person's tax liability arising from the vesting of restricted stock units.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $68.02 to $68.84, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $69.205 to $70.0175, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.02 to $70.25, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
- Each restricted stock unit represents a contingent right to receive one share of common stock.
- On February 23, 2021, the reporting person was granted 23,719 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date.
Billionaire Hedge Funds
